Chicago Capital Management LLC Takes $10.17 Million Position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
Chicago Capital Management LLC Takes $10.17 Million Position in Turning Point Therapeutics, Inc. (NASDAQ:TPTX)
Chicago Capital Management LLC acquired a new stake in shares of Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating) in the 2nd quarter, Holdings Channel.com reports. The institutional investor acquired 135,112 shares of the company's stock, valued at approximately $10,167,000. Turning Point Therapeutics makes up 5.8% of Chicago Capital Management LLC's holdings, making the stock its 9th biggest holding.
据Holdings Channel.com报道,芝加哥资本管理公司在第二季度收购了Turning Point Treateutics,Inc.(纳斯达克代码:TPTX-GET Rating)的新股。该机构投资者购买了135,112股该公司股票,价值约10,167,000美元。Turning Point Treateutics占芝加哥资本管理公司所持股份的5.8%,使该股成为其第九大持股。
Several other institutional investors also recently made changes to their positions in TPTX. Teacher Retirement System of Texas boosted its position in Turning Point Therapeutics by 5.7% in the 1st quarter. Teacher Retirement System of Texas now owns 8,498 shares of the company's stock valued at $228,000 after buying an additional 461 shares during the last quarter. DekaBank Deutsche Girozentrale raised its stake in shares of Turning Point Therapeutics by 2.8% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 17,350 shares of the company's stock valued at $468,000 after purchasing an additional 480 shares in the last quarter. Guggenheim Capital LLC raised its stake in shares of Turning Point Therapeutics by 4.3% in the 1st quarter. Guggenheim Capital LLC now owns 12,307 shares of the company's stock valued at $330,000 after purchasing an additional 504 shares in the last quarter. US Bancorp DE raised its stake in shares of Turning Point Therapeutics by 139.6% in the 1st quarter. US Bancorp DE now owns 1,143 shares of the company's stock valued at $31,000 after purchasing an additional 666 shares in the last quarter. Finally, Captrust Financial Advisors raised its stake in shares of Turning Point Therapeutics by 176.5% in the 1st quarter. Captrust Financial Advisors now owns 1,045 shares of the company's stock valued at $28,000 after purchasing an additional 667 shares in the last quarter. 90.33% of the stock is owned by hedge funds and other institutional investors.
其他几家机构投资者最近也改变了他们在TPTX的头寸。德克萨斯州教师退休系统在第一季度将其在Turning Point Treeutics的地位提升了5.7%。德克萨斯州的教师退休系统在上个季度又购买了461股后,现在拥有8,498股该公司的股票,价值22.8万美元。德意志银行第一季度增持Turning Point Treeutics股份2.8%。德意志银行在上个季度增持了480股后,现在持有17,350股该公司股票,价值46.8万美元。古根海姆资本有限责任公司在第一季度将其在Turning Point Treateutics的股份增加了4.3%。Guggenheim Capital LLC在上个季度又购买了504股,现在拥有12,307股该公司股票,价值33万美元。美国Bancorp DE在第一季度增持了Turning Point Treateutics的股份139.6%。US Bancorp DE现在拥有1143股该公司股票,价值3.1万美元,此前在上个季度又购买了666股。最后,CapTrust Financial Advisors在第一季度将其在Turning Point Treateutics的股份增加了176.5%。CapTrust Financial Advisors在上个季度额外购买了667股后,现在拥有1,045股该公司股票,价值28,000美元。90.33%的股票由对冲基金和其他机构投资者持有。
Turning Point Therapeutics Stock Performance
转折点治疗公司股票表现
Shares of NASDAQ:TPTX traded up $0.52 during trading hours on Monday, hitting $76.01. The stock had a trading volume of 2,843,300 shares, compared to its average volume of 1,137,726. The stock's fifty day simple moving average is $75.81 and its 200 day simple moving average is $59.39. Turning Point Therapeutics, Inc. has a 1-year low of $23.77 and a 1-year high of $82.20. The firm has a market capitalization of $3.81 billion, a price-to-earnings ratio of -11.02 and a beta of -0.18.
纳斯达克:多伦多证券交易所的股价周一在交易时段上涨0.52美元,至76.01美元。该股成交量为2,843,300股,而平均成交量为1,137,726股。该股的50日简单移动均线为75.81美元,200日简单移动均线为59.39美元。Turning Point Treateutics,Inc.的一年低点为23.77美元,一年高位为82.20美元。该公司的市值为38.1亿美元,市盈率为-11.02倍,贝塔系数为-0.18。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Several equities research analysts recently weighed in on the stock. Guggenheim set a $76.00 price objective on shares of Turning Point Therapeutics in a research note on Monday, June 20th. SVB Leerink lowered shares of Turning Point Therapeutics from an "outperform" rating to a "market perform" rating and dropped their price objective for the stock from $101.00 to $76.00 in a research note on Monday, June 13th. Nine investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $78.22.
几位股票研究分析师最近对该股进行了加码。古根海姆在6月20日星期一的一份研究报告中为Turning Point治疗公司的股票设定了76.00美元的目标价格。SVB Leerink在6月13日(星期一)的一份研究报告中将Turning Point Treateutics的股票评级从“跑赢大盘”下调至“市场表现”,并将其股票目标价从101.00美元下调至76美元。九名投资分析师对该股的评级为持有,三名分析师对该公司股票的评级为买入。根据MarketBeat.com的数据,该公司目前的普遍评级为持有,平均目标价为78.22美元。
Insider Activity
内幕活动
In other news, CFO Paolo Tombesi sold 1,183 shares of the stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $74.94, for a total value of $88,654.02. Following the completion of the transaction, the chief financial officer now directly owns 28,700 shares in the company, valued at $2,150,778. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 8.60% of the company's stock.
在其他新闻方面,首席财务官保罗·汤贝西在7月27日星期三的一笔交易中出售了1183股该公司股票。这些股票的平均价格为74.94美元,总价值为88,654.02美元。交易完成后,首席财务官现在直接拥有该公司28,700股,价值2,150,778美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的,该文件可在此超链接。内部人士持有该公司8.60%的股份。
Turning Point Therapeutics Profile
转折点治疗简介
(Get Rating)
(获取评级)
Turning Point Therapeutics, Inc, a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.
Turning Point治疗公司是一家临床阶段的精确肿瘤学生物制药公司,致力于设计和开发针对癌症遗传驱动因素的治疗方法。它开发了一系列酪氨酸激酶抑制剂(TKI),针对TKI-NAI、̈Ve和TKI预治疗患者的癌症基因驱动因素。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Turning Point Therapeutics (TPTX)
- Hormel Foods is More than Just Spam
- Clorox Pandemic Gains Have Been Bleached, Time to Get Back In?
- Could the Crash of the Pound Cause the Fed to Blink on Rates?
- 2 Regional Banks With Sector-Beating Price Performance
- MarketBeat: Week in Review 10/3-10/7
- 免费获取StockNews.com关于转折点治疗(TPTX)的研究报告
- 霍梅尔食品不仅仅是垃圾邮件
- 高乐氏疫情的收益已经被冲淡了,是时候回来了吗?
- 英镑暴跌会不会导致美联储在利率问题上眨眼?
- 2家地区性银行的价格表现优于行业
- MarketBeat:回顾一周10/3-10/7
Want to see what other hedge funds are holding TPTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Turning Point Therapeutics, Inc. (NASDAQ:TPTX – Get Rating).
想看看其他对冲基金持有TPTX的情况吗?访问HoldingsChannel.com获取Turning Point Treateutics,Inc.(纳斯达克代码:TPTX-GET Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得《转折点治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Turning Point Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。